PT  - JOURNAL ARTICLE
AU  - Jouko Levijoki
AU  - Lasse Saloranta
AU  - Johanna Tuunainen
AU  - Janne Kaskinoro
AU  - Sari Pappinen
AU  - Sandra Nourry
AU  - Anne-Marie Betat
AU  - Anne Maurin
AU  - Maarit Pakarinen
AU  - Sari Häkkinen
AU  - Johanna Tervapuro
AU  - Hertta Pihlasvaara
AU  - Christophe Drieu La Rochelle
AU  - Heikki Joensuu
TI  - Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting
AID  - 10.1124/jpet.122.001444
DP  - 2023 Jan 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - JPET-AR-2022-001444
4099  - http://jpet.aspetjournals.org/content/early/2023/01/12/jpet.122.001444.short
4100  - http://jpet.aspetjournals.org/content/early/2023/01/12/jpet.122.001444.full
AB  - Cancer treatments are frequently associated with nausea and vomiting despite greatly improved preventive medication. Administration of anti-nausea agents as eye drops might provide an easy and rapid access to the systemic circulation for prevention of nausea and vomiting and for the treatment of breakthrough nausea, but the ocular administration route has rarely been evaluated. Palonosetron is a second-generation 5-HT3 receptor antagonist approved for prevention and treatment of chemotherapy-induced nausea and vomiting. We compared ocular administration of palonosetron to non-active vehicle eye drops and to intravenous palonosetron in the prevention of cisplatin-induced nausea and vomiting in beagle dogs. Palonosetron ocular drops at the dose of 30 µg/kg reduced cumulative nausea over time as measured with the area under the visual analog scale curve (VAS-AUC) by 98% compared with the vehicle, and reduced nausea-associated dog behavior by 95%. Vomiting was completely prevented with repeated palonosetron ocular dosing. Hydroxypropyl-β-cyclodextrin (HP-β-CD) palonosetron formulation was well tolerated locally at the palonosetron concentration of 3 mg/mL. Absorption of palonosetron from eye drops was fast. Ten minutes after ocular administration, palonosetron plasma concentrations were similar compared to intravenous administration, and remained similar for six hours. We conclude that palonosetron is rapidly absorbed into the systemic circulation from eye drops. Ocularly administered palonosetron was well tolerated in the HP-β-CD formulation and was highly effective in the prevention of cisplatin-induced nausea and vomiting. Evaluation of the safety and efficacy of ocular administration of palonosetron is warranted in the prevention and treatment of chemotherapy-induced nausea and vomiting in clinical trials. Significance Statement Palonosetron, an effective and well-tolerated antiemetic drug was rapidly absorbed into the systemic blood circulation when administered as eye drops. The achieved palonosetron blood concentrations prevented cisplatin-induced nausea and vomiting in beagle dogs. Palonosetron eye drops might provide an easy and quick method for administering palonosetron when parenteral administration is desired and intravenous administration is not feasible.